Core Viewpoint - Stevanato Group S.p.A. will report its financial results for the fourth quarter and fiscal year 2025 on March 4, 2026, at 6:30 a.m. ET, followed by a conference call at 8:30 a.m. ET to discuss the results [1] Financial Results Announcement - The financial results for the fourth quarter and fiscal year 2025 will be released on March 4, 2026, at 6:30 a.m. ET [1] - A conference call and webcast will be held at 8:30 a.m. ET on the same day to discuss the financial results [1] - Participants are encouraged to pre-register for the conference call to gain immediate access [1] Company Overview - Stevanato Group is a leading global provider of drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries [1] - Founded in 1949, the company offers an integrated portfolio of products, processes, and services that address customer needs across the entire drug life cycle [1] - The company's core capabilities include scientific research and development, technical innovation, and engineering excellence [1]

Core Insights - ImmunityBio Inc. (NASDAQ:IBRX) experienced a significant stock price increase, reaching a new 52-week high of $8.68 during intra-day trading, ultimately closing up by 41.86% at $8.54 per share [1] - The European Commission granted conditional marketing authorization for Anktiva + BCG for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), following a positive opinion from the European Medicines Agency [2] - The conditional marketing authorization allows ImmunityBio to sell Anktiva in 33 European countries, enhancing its market presence [3] Company Developments - ImmunityBio has established a broad global access platform for Anktiva, with authorization spanning from the United States and the United Kingdom to the European Union and Saudi Arabia [4] - The company reports that over 80% of treated patients have preserved their bladder through three years of follow-up, indicating the therapy's effectiveness [4]

Core Viewpoint - Serina Therapeutics has enrolled its first patient in a Phase 1b registrational trial for SER-252, targeting advanced Parkinson's disease, which represents a significant operational milestone for the company [1][3]. Group 1: Trial Details - The Phase 1b study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of SER-252 in patients whose symptoms are not adequately managed by existing therapies [2]. - Dosing for the trial is expected to begin in the current quarter, aligning with previously disclosed timelines [2]. Group 2: Company Operations - The company has established a strong operational presence in Australia, collaborating with Parkinson's disease specialists and advocacy groups to facilitate patient enrollment [3]. - Serina has received FDA alignment on its registrational development strategy under a 505(b)(2) NDA pathway, focusing on executing the trial and generating clinical data for patients with significant unmet medical needs [3]. Group 3: Technology and Product Information - Serina Therapeutics is developing SER-252, an investigational apomorphine therapy utilizing the POZ platform, designed to provide continuous dopaminergic stimulation, potentially reducing levodopa-related motor complications in Parkinson's disease [7]. - The POZ platform technology is based on a synthetic polymer that enhances drug loading control and release precision, aiming to improve the efficacy and safety profiles of various therapeutic modalities [5]. Group 4: Future Plans - The company intends to explore additional applications of the POZ platform through out-licensing, co-development, or partnerships, including a non-exclusive license agreement with Pfizer for lipid nanoparticle drug delivery formulations [6].

Core Viewpoint - Eupraxia Pharmaceuticals Inc. has announced a public offering of common shares and pre-funded warrants, aiming to raise approximately US$55 million to advance its clinical programs and expand its pipeline [1][3]. Group 1: Offering Details - The public offering consists of 6,428,574 common shares priced at US$7.00 each and pre-funded warrants to purchase up to 1,428,571 common shares at US$6.99999 each, resulting in gross proceeds of about US$55 million before expenses [1]. - The offering is expected to close on February 20, 2026, pending customary closing conditions, including the listing of shares on the TSX and Nasdaq [1]. - Underwriters have a 30-day option to purchase an additional 1,178,571 common shares under the same terms [1]. Group 2: Use of Proceeds - The net proceeds will primarily fund the advancement of EP-104GI for Eosinophilic Esophagitis, including ongoing preclinical studies and Phase 2 clinical trials, as well as preparations for a Phase 3 trial [3]. - A portion of the funds will be allocated to expand clinical studies for EP-104GI in additional gastrointestinal indications and to support research and development of other pipeline candidates [3]. - The proceeds may also be used for general corporate purposes, including employee salaries, working capital, and expanding the intellectual property portfolio [3]. Group 3: Company Overview - Eupraxia Pharmaceuticals is a clinical-stage biotechnology company focused on developing locally delivered, extended-release products targeting high unmet medical needs [7]. - The company utilizes its proprietary Diffusphere™ technology for optimized local drug delivery [7].

Company Overview - argenx is a global immunology company focused on improving the lives of individuals suffering from severe autoimmune diseases [3] - The company is known for developing and commercializing the first approved neonatal Fc receptor (FcRn) blocker, with ongoing evaluations of its potential in various serious autoimmune diseases [3] Upcoming Events - argenx will host a conference call and audio webcast on February 26, 2026, at 2:30 PM CET (8:30 AM ET) to discuss its full year 2025 financial results and provide a fourth quarter business update [1] - The live call can be accessed via the Investors section of the argenx website, with a replay available for approximately one year following the presentation [2] Contact Information - Media inquiries can be directed to Ben Petok at bpetok@argenx.com [4] - Investor relations can be contacted through Alexandra Roy at aroy@argenx.com [4]

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce†and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF†) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate†or the "Company†) releases its total number of shares outstanding as well as its voting rights as of February 19, 2026: Total number of shares outstanding: 93,743,243 ordinary shares 6,140 Preferred ...

Core Insights - Zealand Pharma experienced significant growth in 2025, highlighted by a transformative partnership with Roche for petrelintide and strong clinical advancements, setting the stage for a pivotal 2026 [1][2] Financial Performance - Revenue for FY 2025 reached DKK 9,215 million, a substantial increase from DKK 63 million in FY 2024 [3] - Net operating expenses, excluding other operating items, were DKK -2,101 million, compared to DKK -1,324 million in FY 2024 [3] - The operating result improved to DKK 6,959 million from a loss of DKK -1,272 million in FY 2024 [3] - Cash position at the end of FY 2025 was DKK 15,109 million, up from DKK 9,022 million in FY 2024 [4] 2026 Financial Guidance - Expected net operating expenses for 2026 are projected to be between DKK 2,700 million and DKK 3,300 million, primarily driven by research and development activities [5][7] - Zealand Pharma is eligible for potential milestone payments from Roche totaling USD 700 million, including a development milestone of USD 575 million and an anniversary payment of USD 125 million [8] Strategic Developments - Zealand Pharma aims to establish a leading amylin-based franchise around petrelintide, with plans for a Phase 3 program initiation in H2 2026 [5][10] - The company outlined its ambitious Metabolic Frontier 2030 strategy, targeting five product launches and over 10 clinical pipeline programs by 2030 [5] - A new research site in Boston is planned to enhance drug discovery capabilities, integrating AI-driven approaches with over 25 years of peptide expertise [5][15] Clinical Pipeline and Milestones - Phase 2 data from the ZUPREME-1 trial for petrelintide is expected to be reported imminently, with Phase 3 development anticipated to begin soon after [2][10] - Survodutide's Phase 3 data from the SYNCHRONIZETM program is also expected to be reported throughout 2026, potentially leading to regulatory submissions [2][10] Organizational Growth - Zealand Pharma saw a 41% increase in employee count in 2025, with an improved employee engagement score of 8.9 out of 10 and a low turnover rate of 7.8% [15]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, of the upcoming lead plaintiff deadline on April 7, 2026, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Inovio securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the Court by April 7, 2026 [3]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field [4]. Group 3: Case Background - Inovio Pharmaceuticals is described as a biotechnology company focused on DNA medicines for diseases like human papillomavirus (HPV) [5]. - The lawsuit alleges that Inovio made false or misleading statements regarding the manufacturing of its CELLECTRA device and the prospects of its INO-3107 Biologics License Application (BLA) to the FDA, which were overstated [5].

GH Research PLC (NASDAQ:GHRS) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. RBC Capital Cite GH Research PLC's (GHRS) Long-Term Sales Potential Following Psychedelics Symposium GH Research PLC (NASDAQ:GHRS) is placed sixth on our list. TheFly reported that on January 23, RBC Capital raised its price target on GHRS to $40 from $33 and maintained an Outperform rating. RBC stated that it was growing more hopeful about GHRS's long-term sales potential, particularly GH001, follow ...

A Japanese health ministry panel is set to review two regenerative therapies facing regulatory approval, a pivotal test of the country’s long-running push to build a domestic industry around advanced cell-based treatments https://t.co/d2b7d7Lng3 ...